Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Gastrointestinal Stromal Tumors 12Leukemia, Myeloid, Chronic-Phase 9Leukemia 7Leukemia, Myeloid, Acute 6Blast Crisis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myeloid, Accelerated Phase 5Gliosarcoma 5Glioblastoma 5Brain Neoplasms 5Glioma 4Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Philadelphia Chromosome 3Pancreatic Neoplasms 3Oligodendroglioma 3Myeloproliferative Disorders 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Central Nervous System Neoplasms 3Astrocytoma 3Primary Myelofibrosis 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Congenital Bone Marrow Failure Syndromes × Imatinib Mesylate × Clear all
NCT06090669 2026-06-03

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
75 enrolled
Classical hematology

Congenital Bone Marrow Failure Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡